KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Assets (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Assets for 16 consecutive years, with $40.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 3.62% year-over-year to $40.7 billion, compared with a TTM value of $40.7 billion through Dec 2025, up 3.62%, and an annual FY2025 reading of $40.7 billion, up 3.62% over the prior year.
  • Assets was $40.7 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $39.9 billion in the prior quarter.
  • Across five years, Assets topped out at $49.2 billion in Q2 2021 and bottomed at $38.4 billion in Q1 2025.
  • Average Assets over 5 years is $43.7 billion, with a median of $43.5 billion recorded in 2023.
  • The sharpest move saw Assets decreased 11.43% in 2021, then grew 3.62% in 2025.
  • Year by year, Assets stood at $47.7 billion in 2021, then dropped by 7.67% to $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then grew by 3.62% to $40.7 billion in 2025.
  • Business Quant data shows Assets for TEVA at $40.7 billion in Q4 2025, $39.9 billion in Q3 2025, and $40.1 billion in Q2 2025.